Beijing SL Pharmaceutical Co Ltd Asset Resilience Ratio
Beijing SL Pharmaceutical Co Ltd asset resilience ratio. Beijing SL Pharmaceutical Co Ltd (002038) has an Asset Resilience Ratio of 8.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing SL Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beijing SL Pharmaceutical Co Ltd (2003–2025)
Asset resilience ratio of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. This chart shows how Beijing SL Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Beijing SL Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Beijing SL Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Beijing SL Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥512.01 Million | 8.77% |
| Total Liquid Assets | CN¥512.01 Million | 8.77% |
Asset Resilience Insights
- Limited Liquidity: Beijing SL Pharmaceutical Co Ltd maintains only 8.77% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beijing SL Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing SL Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Beijing SL Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2003–2025)
Beijing SL Pharmaceutical Co Ltd asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Beijing SL Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.22% | CN¥498.95 Million ≈ $73.01 Million |
CN¥6.07 Billion ≈ $888.54 Million |
+0.17pp |
| 2024-12-31 | 8.04% | CN¥480.86 Million ≈ $70.36 Million |
CN¥5.98 Billion ≈ $874.92 Million |
-15.04pp |
| 2023-12-31 | 23.08% | CN¥1.45 Billion ≈ $212.06 Million |
CN¥6.28 Billion ≈ $918.63 Million |
+8.48pp |
| 2022-12-31 | 14.61% | CN¥858.27 Million ≈ $125.59 Million |
CN¥5.88 Billion ≈ $859.82 Million |
+11.79pp |
| 2021-12-31 | 2.82% | CN¥162.36 Million ≈ $23.76 Million |
CN¥5.76 Billion ≈ $842.94 Million |
-0.40pp |
| 2020-12-31 | 3.22% | CN¥173.81 Million ≈ $25.43 Million |
CN¥5.39 Billion ≈ $789.43 Million |
+0.53pp |
| 2019-12-31 | 2.69% | CN¥140.45 Million ≈ $20.55 Million |
CN¥5.22 Billion ≈ $764.58 Million |
+2.09pp |
| 2018-12-31 | 0.59% | CN¥29.65 Million ≈ $4.34 Million |
CN¥4.99 Billion ≈ $729.94 Million |
-0.94pp |
| 2017-12-31 | 1.53% | CN¥70.31 Million ≈ $10.29 Million |
CN¥4.59 Billion ≈ $670.94 Million |
+0.64pp |
| 2016-12-31 | 0.89% | CN¥36.48 Million ≈ $5.34 Million |
CN¥4.08 Billion ≈ $597.22 Million |
-0.14pp |
| 2015-12-31 | 1.03% | CN¥38.73 Million ≈ $5.67 Million |
CN¥3.76 Billion ≈ $550.44 Million |
+0.74pp |
| 2014-12-31 | 0.29% | CN¥9.47 Million ≈ $1.39 Million |
CN¥3.32 Billion ≈ $485.68 Million |
+0.05pp |
| 2013-12-31 | 0.23% | CN¥6.35 Million ≈ $929.58K |
CN¥2.71 Billion ≈ $396.87 Million |
-0.17pp |
| 2012-12-31 | 0.40% | CN¥8.91 Million ≈ $1.30 Million |
CN¥2.22 Billion ≈ $324.37 Million |
-0.10pp |
| 2011-12-31 | 0.51% | CN¥8.78 Million ≈ $1.29 Million |
CN¥1.74 Billion ≈ $254.05 Million |
-0.42pp |
| 2010-12-31 | 0.93% | CN¥11.57 Million ≈ $1.69 Million |
CN¥1.25 Billion ≈ $182.71 Million |
-1.22pp |
| 2009-12-31 | 2.14% | CN¥21.86 Million ≈ $3.20 Million |
CN¥1.02 Billion ≈ $149.23 Million |
+0.59pp |
| 2008-12-31 | 1.55% | CN¥12.22 Million ≈ $1.79 Million |
CN¥788.52 Million ≈ $115.38 Million |
-3.74pp |
| 2007-12-31 | 5.29% | CN¥31.05 Million ≈ $4.54 Million |
CN¥586.63 Million ≈ $85.84 Million |
+1.66pp |
| 2005-12-31 | 3.64% | CN¥14.76 Million ≈ $2.16 Million |
CN¥405.91 Million ≈ $59.40 Million |
-5.59pp |
| 2003-12-31 | 9.22% | CN¥14.00 Million ≈ $2.05 Million |
CN¥151.83 Million ≈ $22.22 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more